Novel STAT5 Targets FasL in AML
Experts discuss miR-590, a novel STAT5 oncogenic miRNA that targets FasL in AML.
ASH 2013
AE Reporting Sensitivity Relatively Low in Cooperative Group Trials
The current system of AE reporting has modest sensitivity and a demonstrable false positive rate in cooperative group trials.
Telomere Length Associated with Women’s Cognition after HCT
Telomere length may be prognostic of cognitive impairment in women after HCT.
ABT-199 Shows Activity in High-Risk Relapsed/Refractory CLL
ABT-199 (GDC-0199) demonstrated antitumor activity in patients with high-risk relapsed/refractory CLL and SLL.
Biomarkers, AlloHSCT Predict Post-AML Relapse Prognosis
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
Combo Ofatumumab/Chlorambucil Improved PFS in CLL with Comorbidities
Ofatumumab plus chlorambucil prolongs PFS in older patients with CLL and comorbidities.
Long-term Rituximab Maintenance Doubled PFS in Follicular Lymphoma
Long-term rituximab maintenance prolongs PFS in follicular lymphoma.
New Assay Paves Way for ‘Personalized’ Therapy in AML
High-throughput sensitivity assay may make “personalized” therapy possible in relapsed or refractory AML.
RiBVD Benefits Elderly with Untreated Mantle Cell Lymphoma
RiBVD regimen appears effective in elderly patients with untreated mantle cell lymphoma.
Crizotinib Yields High Response Rates in ALK-positive Lymphoma
High response rates to crizotinib were seen in advanced, chemoresistant ALK-positive lymphoma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...